Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases, rheumatoid arthritis (RA), and antineutrophil cytoplasmic antibodyassociated vasculitis. Treatment of ILD, mainly based on immunosuppression, remains challenging. Rituximab (RTX), a monoclonal a...

Full description

Bibliographic Details
Main Authors: Caterina Vacchi, Andreina Manfredi, Giulia Cassone, Gian Luca Erre, Carlo Salvarani, Marco Sebastiani
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2021-01-01
Series:Drugs in Context
Subjects:
connective tissue diseases
efficacy
interstitial lung disease
lung fibrosis
rheumatic diseases
rituximab
safety
Online Access:https://www.drugsincontext.com/efficacy-and-safety-of-rituximab-in-the-treatment-of-connective-tissue-disease-related-interstitial-lung-disease

Internet

https://www.drugsincontext.com/efficacy-and-safety-of-rituximab-in-the-treatment-of-connective-tissue-disease-related-interstitial-lung-disease

Similar Items